Akihiro Inano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Akihiro Inano has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Akio Morita
Department of Neurological Surgery, Nippon Medical School, Tokyo, Japan
1 shared publication Akira Ishii
Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
1 shared publication- Akitake Mukasa
Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto City, Japan
1 shared publication - Fumiaki Takahashi
Department of Information Science, Iwate Medical University, Morioka, Japan
1 shared publication Hidekichi Tokai
Osaka City University Hospital, Center for Drug & Food Clinical Evaluation, 1-2-7 Asahimachi, Abeno-ku, Osaka 545-0051, Japan
1 shared publication- Hirofumi Nakatomi
Department of Neurosurgery, University of Tokyo, Bunkyo-Ku, Tokyo 113-8654, Japan
1 shared publication
Latest Publications
- Open Access
- 31 January 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 726-739
Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma
Neurofibromatosis type 2 (NF2) causes bilateral vestibular schwannomas (VSs), leading to deafness. VS is treated by surgery or radiation, but neither treatments prevent hearing loss. Bevacizumab was found to be effective in suppressing the tumor’s growth and may help to improve hearing. We are conducting a randomized, double-blind, multicenter clinical trial to verify the efficacy and safety of bevacizumab in NF2-related VS. The primary objective is to evaluate the efficacy of bevacizumab in improving hearing in the affected ear. One of the secondary objectives is to evaluate bevacizumab’s efficacy in rechallenge treatment in relapsed cases. Sixty patients will randomly receive either bevacizumab or a placebo and will be clinically observed for 48 weeks in the initial intervention phase. In the first half (24 weeks), they will receive either 5 mg/kg of bevacizumab or a placebo drug. In the second half, all patients will receive 5 mg/kg of bevacizumab. If hearing function deteriorated in a patient who had shown improvement during the first phase, a rechallenge dose with bevacizumab would be offered.
- 31 January 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 726-739
Open AccessRationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma
Neurofibromatosis type 2 (NF2) causes bilateral vestibular schwannomas (VSs), leading to deafness. VS is treated by surgery or radiation, but neither treatments prevent hearing loss. Bevacizumab was found to be effective in suppressing the tumor’s growth and may help to improve hearing. We are conducting a randomized, double-blind, multicenter clinical trial to verify the efficacy and safety of bevacizumab in NF2-related VS. The primary objective is to evaluate the efficacy of bevacizumab in improving hearing in the affected ear. One of the secondary objectives is to evaluate bevacizumab’s efficacy in rechallenge treatment in relapsed cases. Sixty patients will randomly receive either bevacizumab or a placebo and will be clinically observed for 48 weeks in the initial intervention phase. In the first half (24 weeks), they will receive either 5 mg/kg of bevacizumab or a placebo drug. In the second half, all patients will receive 5 mg/kg of bevacizumab. If hearing function deteriorated in a patient who had shown improvement during the first phase, a rechallenge dose with bevacizumab would be offered.
- 1 December 2017
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 32 (6) , 293-300
Comparison of pharmacokinetics of newly discovered aromatase inhibitors by a cassette microdosing approach in healthy Japanese subjects
- 1 December 2017
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 32 (6) , 293-300
Comparison of pharmacokinetics of newly discovered aromatase inhibitors by a cassette microdosing approach in healthy Japanese subjects